---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-283693"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:02:31.628593+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics appoints Cameron Turtle CEO; name change to Spyre, ticker SYRE effective Nov 28

## Summary
- Cameron Turtle, previously COO, appointed CEO and director; $625K base, 55% target bonus, option for 374K shares at $10.39.
- Name change from Aeglea BioTherapeutics to Spyre Therapeutics; ticker changes from AGLE to SYRE effective Nov 28, 2023.
- Directors Ivana Magovčević-Liebisch and Hunter Smith resign; Laurie Stelzer (chair audit) and Jeffrey Albers appointed to board.
- Pipeline on track: SPY001 (anti-α4β7) FIH H1 2024; SPY002 (anti-TL1A) FIH H2 2024; SPY003 (anti-IL-23) IND 2025; cash $205M into 2026.

## SEC filing metadata
- accession: 0001193125-23-283693
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312523283693/0001193125-23-283693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312523283693/d610145d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-283693
- JSON: https://secwatch.observer/filing/0001193125-23-283693.json
- Plain text: https://secwatch.observer/filing/0001193125-23-283693.txt

## Key facts
- Executive change
  Cameron Turtle was appointed as Chief Executive Officer at Spyre Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: appointed Cameron Turtle, DPhil, as Chief Executive Officer of the Company, effective as of November 22, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523283693/0001193125-23-283693-index.htm
- Executive change
  Hunter C. Smith resigned as Director at Spyre Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Ivana Magovčević-Liebisch, Ph.D., J.D. and Hunter C. Smith, M.B.A. resigned from the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523283693/0001193125-23-283693-index.htm
- Executive change
  Ivana Magovčević-Liebisch resigned as Director at Spyre Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Ivana Magovčević-Liebisch, Ph.D., J.D. and Hunter C. Smith, M.B.A. resigned from the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523283693/0001193125-23-283693-index.htm
- Governance Changes
  Spyre Therapeutics, Inc.: Amended and restated Certificate of Incorporation to change company name from Aeglea BioTherapeutics, Inc. to Spyre Therapeutics, Inc (effective 2023-11-28).
  - Change: charter amendment
  - Effective: 2023-11-28
  source text: On November 27, 2023, the Company filed an amended and restated Certificate of Incorporation ("Amended and Restated Certificate of Incorporation") with the Secretary of State of the State of Delaware to change the name of the Company from "Aeglea BioTherapeutics, Inc." to "Spyre Therapeutics, Inc." (the "Name Change")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523283693/0001193125-23-283693-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.